China: Green Valley Alzheimer’s Trial; Samsung Biologics Expansion; Fosun Ends COVID-19 Vaccine Development

face
main_img

A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to the development of a COVID-19 vaccine; and CAR-T biotech JW Therapeutics raising USD 300m in its IPO on the Hong Kong Stock Exchange

 

China’s Green Valley prepares US trial of Alzheimer’s drug inspired by algae

https://pharmaphorum.com/news/chinas-green-valley-prepares-us-trial-of-alzheimers-drug-inspired-by-algae/

As an influential panel of FDA-appointed experts prepares its verdict on Biogen’s Alzheimer’s drug, a little known China-based pharma is hoping to succeed where big name rivals have failed and develop a drug that is effective against the disease.

 

Samsung Biologics Expands in China and Partners with Chinese biotech GeneQuantum Healthcare on ADC development

https://www.contractpharma.com/contents/view_breaking-news/2020-11-03/samsung-biologics-expands-in-china/

Samsung Biologics has entered into a partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors. The agreement signals Samsung Biologics’ accelerated entry into the China market.

 

Fosun Pharma has stopped development of BioNTech’s first COVID-19 vaccine, following the lead of its German partner by picking BNT162b2 as the candidate to take to market

https://www.fiercebiotech.com/biotech/fosun-follows-biontech-changing-covid-19-vaccine-plans-bridging-study-for-chinese-filing

Fosun Chief Medical Officer Aimin Hui has told Reuters that BNT162b2 is also the preferred shot for the Chinese market. Fosun has opted against further development of BNT162b1, choosing instead to run a bridging study that may enable it to use global BNT162b2 data to support approval in China.

 

Australia’s Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market 

https://www.globenewswire.com/news-release/2020/11/02/2118106/0/en/Telix-Pharmaceuticals-and-China-Grand-Pharma-Announce-Strategic-Licence-and-Commercial-Partnership-for-Greater-China-Market.html

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.

 

Japanese pharmaceutical maker Shionogi will design new drugs and health care services by accessing a database spanning over 300 million people maintained by China’s Ping An Insurance Group

https://asia.nikkei.com/Business/Pharmaceuticals/Japan-drugmaker-taps-Ping-An-s-database-of-300m-people-in-China

“You can do things in China that you can’t do in Japan,” Teshirogi said at a news conference with Ping An last month. “The level of freedom is substantially high.”

 

China based CAR-T biotech, JW Therapeutics, has raised USD 300m in its IPO on the Hong Kong Stock Exchange

https://www.biopharma-reporter.com/Article/2020/11/05/Chinese-cell-therapy-player-generates-300m-in-IPO

Those funds add to the $190m in venture capital JW has secured over three funding rounds. The company is funded by 13 investors, with CPE and Mirae Asset Global Investments its most recent backers. 

 

Porton Biologics Launched Gene and Cell Therapy CDMO Platform to Rank Among the Top of Pharma Solutions Platforms

https://finance.yahoo.com/news/porton-biologics-launched-gene-cell-073500706.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJdtl8qZmuUctlNznnK12Vfq_8OpVO4GdLErwFZ9jSJ0kvxRMTPQmUaZikslvZWZZcbe0AjOGQd_CBsGxKvfL4mC9CnxfS7iPHqQ3jRQHuYvv3s0mHRA9aFifGjDVtnuu4dQR94aP3krsnhtBgQMrmA5lK3B7USpQhl30ha3_OTJ

Mr. Ju Nianfeng, Chairman of Porton Biologics, said, “With over 15 years of efforts, Porton has built a small molecule CDMO platform providing world-leading technologies and services. Now, we put a great amount of effort in the gene and cell therapy CDMO services, as we aim to build a world-leading R&D and production platform depending on core talents and technical skills.”

 

CEPI will invest up to USD 328 million to help Clover Biopharmaceuticals develop a coronavirus vaccine, boosting its funding after previously committing nearly $70 million to the effort earlier this year

https://www.biopharmadive.com/news/clover-cepi-coronavirus-vaccine-funding/588296/

Clover will use the money for a late-stage trial slated to begin before the end of 2020 as well as for studies in special populations, such as people with autoimmune conditions and pregnant women, the China-based biotech said.

 

Chinese biotech firm BGI sees booming revenue, profits in first 3 quarters

http://www.china.org.cn/china/Off_the_Wire/2020-11/01/content_76865701.htm 

The company reported 2.71 billion yuan (about 403 million U.S. dollars) in net profits for its parent company in the first nine months, soaring 901.68 percent year on year, according to its report filed with the Shenzhen Stock Exchange.

Add Your Comment


You must be logged in to post a comment.

Related Content

Latest Report